Literature DB >> 26773042

Polycomb-dependent epigenetic landscape in adult T-cell leukemia.

Dai Fujikawa1, Shota Nakagawa1, Makoto Hori1, Naoya Kurokawa1, Ai Soejima1, Kazumi Nakano1, Tadanori Yamochi1, Makoto Nakashima1, Seiichiro Kobayashi2, Yuetsu Tanaka3, Masako Iwanaga4, Atae Utsunomiya5, Kaoru Uchimaru2, Makoto Yamagishi1, Toshiki Watanabe1.   

Abstract

Adult T-cell leukemia-lymphoma (ATL) shows global gene expression alterations that confer cellular characteristics and unfavorable prognosis. However, molecular mechanisms of the sustained expression changes are largely unknown, because there is no study addressing the relationship between landscapes of the gene expression and epigenetic modifications. Here, we analyzed ATL epigenome and integrated it with transcriptome from primary ATL cells and those from corresponding normal CD4(+)T cells to decipher ATL-specific "epigenetic code" that was critical for cell identity. We found that polycomb-repressive complex 2 (PRC2)-mediated trimethylation at histone H3Lys27 (H3K27me3) was significantly and frequently reprogrammed at half of genes in ATL cells. A large proportion of the abnormal gene downregulation was detected at the early stage of disease progression and was explained by H3K27me3 accumulation. The global H3K27me3 alterations involved ATL-specific gene expression changes that included several tumor suppressors, transcription factors, epigenetic modifiers, miRNAs, and developmental genes, suggesting diverse outcomes by the PRC2-dependent hierarchical regulation. Interestingly, a key enzyme, EZH2, was sensitive to promiscuous signaling network including the NF-κB pathway and was functionally affected by human T-cell leukemia virus type I (HTLV-1) Tax. The Tax-dependent immortalized cells showed H3K27me3 reprogramming that was significantly similar to that of ATL cells. Of note, a majority of the epigenetic silencing has occurred in leukemic cells from indolent ATL and also in HTLV-1-infected T cells from asymptomatic HTLV-1 carriers. Because pharmacologic inhibition of EZH2 reversed epigenetic disruption and selectively eliminated leukemic and HTLV-1-infected cells, targeting the epigenetic elements will hold great promise in treatment and prevention of the onset of ATL and HTLV-1-related diseases.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26773042     DOI: 10.1182/blood-2015-08-662593

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?

Authors:  William Johnson; Anjali Mishra; Adam Binder; Alejandro Gru; Pierluigi Porcu
Journal:  Haematologica       Date:  2019-05       Impact factor: 9.941

Review 2.  Molecular biology of human T cell leukemia virus.

Authors:  Lee Ratner
Journal:  Semin Diagn Pathol       Date:  2019-04-16       Impact factor: 3.464

3.  HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia.

Authors:  Jingyu Xiang; Daniel A Rauch; Devra D Huey; Amanda R Panfil; Xiaogang Cheng; Alison K Esser; Xinming Su; John C Harding; Yalin Xu; Gregory C Fox; Francesca Fontana; Takayuki Kobayashi; Junyi Su; Hemalatha Sundaramoorthi; Wing Hing Wong; Yizhen Jia; Thomas J Rosol; Deborah J Veis; Patrick L Green; Stefan Niewiesk; Lee Ratner; Katherine N Weilbaecher
Journal:  JCI Insight       Date:  2019-10-03

4.  MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells.

Authors:  Arun K Rooj; Franz Ricklefs; Marco Mineo; Ichiro Nakano; E Antonio Chiocca; Agnieszka Bronisz; Jakub Godlewski
Journal:  Cell Rep       Date:  2017-06-06       Impact factor: 9.423

Review 5.  Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma.

Authors:  Hiroo Katsuya; Kenji Ishitsuka
Journal:  J Clin Exp Hematop       Date:  2017-06-08

Review 6.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

7.  HMGA1 induces EZH2 overexpression in human B-cell lymphomas.

Authors:  Marco De Martino; Pedro Nicolau-Neto; Luis Felipe Ribeiro Pinto; Alexandra Traverse-Glehen; Emmanuel Bachy; Vincenzo Gigantino; Rossella De Cecio; Francesco Bertoni; Paolo Chieffi; Alfredo Fusco; Francesco Esposito
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 8.  EZH2-Targeted Therapies in Cancer: Hype or a Reality.

Authors:  Marie-Lisa Eich; James E Ferguson; Sooryanarayana Varambally; Mohammad Athar
Journal:  Cancer Res       Date:  2020-09-25       Impact factor: 12.701

9.  Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.

Authors:  Zaowen Song; Wencai Wu; Mengyun Chen; Wenzhao Cheng; Juntao Yu; Jinyong Fang; Lingling Xu; Jun-Ichirou Yasunaga; Masao Matsuoka; Tiejun Zhao
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

10.  Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.

Authors:  Regina Wan Ju Wong; Phuong Cao Thi Ngoc; Wei Zhong Leong; Alice Wei Yee Yam; Tinghu Zhang; Kaori Asamitsu; Shinsuke Iida; Takashi Okamoto; Ryuzo Ueda; Nathanael S Gray; Takashi Ishida; Takaomi Sanda
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.